Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MACOP-B regimen

Known as: Methotrexate-Adriamycin-Cytoxan-Oncovin-Prednisone-Bleomycin Regimen 
A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non… Expand
National Institutes of Health

Related topics

Related topics

11 relations

Broader (6)

Antineoplastic Combined Chemotherapy ProtocolsBleomycinCyclophosphamideMethotrexate
Expand
DoxorubicinLeucovorin CalciumLymphoma, Non-HodgkinPrednisone
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.
BACKGROUND AND OBJECTIVES Common methylenetetrahydrofolate reductase gene variants (MTHFR C677T and A1298C) have been described… Expand
Is this relevant?
2007
2007
HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen
Loss of major histocompatibility class II (MHC class II) molecules on diffuse large B-cell lymphoma (DLBCL) has been associated… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B
The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined. In the absence of randomised… Expand
  • figure 1
  • table 3
  • table 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients.
To evaluate the efficacy of a combined modality treatment (MACOP-B plus mediastinal radiotherapy) and the advantages of Gallium… Expand
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
1997
Highly Cited
1997
High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.
BACKGROUND We compared a regimen of six chemotherapeutic agents administered sequentially at high doses, followed by… Expand
Is this relevant?
1994
1994
Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
PURPOSE To compare complete response rates, time to failure, survival, and toxicity for patients with intermediate-grade non… Expand
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
BACKGROUND CHOP is a first-generation, combination-chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine… Expand
Is this relevant?
1992
1992
MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study.
PURPOSE The prognosis of advanced-stage diffuse large-cell lymphoma (DLCL) has improved with the use of the third-generation… Expand
Is this relevant?
Highly Cited
1990
Highly Cited
1990
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.
While diffuse large-cell lymphoma (DLCL) is considered to be highly curable with current therapy, treatment failures are observed… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
1985
Highly Cited
1985
MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.
Between April 1981 and May 1984, 61 patients with advanced diffuse large-cell lymphoma completed treatment with MACOP-B… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE